NCT04683029View on ClinicalTrials.gov

A Study of Guselkumab in Participants With Systemic Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

February 24, 2021

Primary Completion Date

May 17, 2023

Study Completion Date

July 9, 2024

Conditions
Scleroderma, Systemic
Interventions
DRUG

Guselkumab Dose 1

Guselkumab Dose 1 will be administered intravenously.

DRUG

Guselkumab Dose 2

Guselkumab Dose 2 will be administered subcutaneously.

DRUG

Placebo

Placebo will be administered intravenously or subcutaneously.

Trial Locations (4)

457 8510

Chukyo Hospital, Aichi

113-8655

The University of Tokyo Hospital, Tokyo

641 8510

Wakayama Medical University Hospital, Wakayama

910-1193

University of Fukui Hospital, Yoshida

Sponsors
All Listed Sponsors
lead

Janssen Pharmaceutical K.K.

INDUSTRY